Key Highlights

  • The FDA's drug evaluation center has formed a board to oversee and advise on drug exclusivity determinations.
  • The board will focus on 5-year new chemical entity exclusivity and 3-year new clinical trial exclusivity grants.
  • FDA-granted exclusivity gives newly approved drugs a period of market protection before generic competitors can enter.
  • The board will also advise on exclusivity determinations for biological products, the agency said.

A New Oversight Layer

The FDA's Center for Drug Evaluation and Research said Friday it has formed a board to oversee and advise on exclusivity determinations made by the department, aiming to improve the clarity and consistency of those decisions. FDA-granted exclusivity rewards innovation by giving newly approved drugs a period of market protection before lower cost generic competitors can enter the market.

What the Board Will Review

The exclusivity board will oversee certain determinations, including whether and what type of exclusivity should be granted and the appropriate scope of each grant, the agency said. Its focus includes 5-year new chemical entity exclusivity, granted to drugs whose active ingredient has never previously been approved by the FDA, and 3-year new clinical trial exclusivity, meant for drugs that rely on a previously approved active ingredient but whose approval depends on new clinical studies conducted or funded by the drug's sponsor. The board will also advise on exclusivity determinations for biological products, though it will not review other categories of exclusivity beyond these three.

Broader Mandate

Beyond individual determinations, the board may evaluate and make recommendations regarding the center's broader policies and practices relating to exclusivity, and it will maintain records of exclusivity determinations going forward.

Regulatory Steps to Watch

Drugmakers and generic manufacturers are watching how quickly the new board begins issuing determinations, and whether its involvement changes the pace or consistency of exclusivity rulings compared with the FDA's prior process.